Last reviewed · How we verify

NCT01462604

Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer

Completed Last updated 19 June 2018
What this trial tests

trial testing non-drug intervention educational programme in Cancer in 27 participants. Completed in 24 January 2013.

Timeline
23 November 2011
Primary endpoint
1 January 2013
24 January 2013

Quick facts

Lead sponsorGlaxoSmithKline
StatusCompleted
Study typeOBSERVATIONAL
Enrollment27
Start date23 November 2011
Primary completion1 January 2013
Estimated completion24 January 2013
Sites7 locations across Pakistan, Hong Kong, Singapore, South Korea

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

18 and older, female only, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 6-week, single arm, pilot study to test the study procedure, educational materials, and measurement instruments for the educational intervention in HER2 overexpressing metastatic or advanced breast cancer patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01462604.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing